From WashPo for the layman, why we should be excited by the lymphatic system developments.
NIH Director Francis Collins’ blog on an antibody that potentially makes the tau protein detectable in blood
A need exists for a simple, less-invasive test to diagnose Alzheimer’s disease and similar neurodegenerative conditions in living people, perhaps even before memory loss becomes obvious.
Exciting news in the hunt for novel AD-related biomarkers: Learn more about the “memory protein” – NPTX2
Memory loss in Alzheimer’s disease (AD) is attributed to pervasive weakening and loss of synapses. Here, we present findings supporting a special role for excitatory synapses connecting pyramidal neurons of the hippocampus and cortex with fast-spiking parvalbumin (PV) interneurons that control network excitability and rhythmicity.
View the best moments of the 13th International Conference on Alzheimer’s & Parkinson’s Diseases. Mechanisms, Clinical Strategies, and Promising Treatments of Neurodegenerative Diseases
Held in the historic Austrian capital, the 13th AD/PD conference reflected a rapidly growing field. The meeting jammed science into five parallel sessions, with 545 talks running from early morning till late evening and some 1,200 posters vying for attention.
Read “Rates of Cortical Atrophy in Adults 80 Years and Older With Superior vs Average Episodic Memory”
Read the Alzheimer’s Forum analysis of the new AD-genetic risk score developed by Rahul Desikan (UCSF), Ole Andreassen (University of Oslo), Anders Dale (UCSD) and colleagues.
In lieu of a crystal ball that can foresee Alzheimer’s, scientists are trying to divine impending disease by looking deep into a person’s genome.
Read the exceptional compilation of AD-related data and statistics. Includes a Special Report on the Next Frontier of Alzheimer’s Research
Maria Carrillo, PhD, Chief Science Officer, Alzheimer’s Association discussing government, industry and the Alzheimer’s Association collaborations in larger scale trials and innovative projects.
As baby boomers age, an unprecedented number of people will be diagnosed with Alzheimer’s disease. The economic and social impacts will be wide reaching from cost of treatment to the effect on caregivers.